AU2020213746A1 - A dosage regime and method for treating pulmonary arterial hypertension with rodatristat ethyl - Google Patents

A dosage regime and method for treating pulmonary arterial hypertension with rodatristat ethyl Download PDF

Info

Publication number
AU2020213746A1
AU2020213746A1 AU2020213746A AU2020213746A AU2020213746A1 AU 2020213746 A1 AU2020213746 A1 AU 2020213746A1 AU 2020213746 A AU2020213746 A AU 2020213746A AU 2020213746 A AU2020213746 A AU 2020213746A AU 2020213746 A1 AU2020213746 A1 AU 2020213746A1
Authority
AU
Australia
Prior art keywords
kar5585
dose
day
kar5417
auc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020213746A
Other languages
English (en)
Inventor
Magdalena Alonso-Galicia
Eric J. Gaukel
Michelle PALACIOS
Stephen A. Wring
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Altavant Sciences GmbH
Original Assignee
Altavant Sciences GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altavant Sciences GmbH filed Critical Altavant Sciences GmbH
Publication of AU2020213746A1 publication Critical patent/AU2020213746A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2020213746A 2019-01-30 2020-01-30 A dosage regime and method for treating pulmonary arterial hypertension with rodatristat ethyl Abandoned AU2020213746A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962798827P 2019-01-30 2019-01-30
US62/798,827 2019-01-30
PCT/IB2020/000074 WO2020157577A1 (en) 2019-01-30 2020-01-30 A dosage regime and method for treating pulmonary arterial hypertension with rodatristat ethyl

Publications (1)

Publication Number Publication Date
AU2020213746A1 true AU2020213746A1 (en) 2021-08-19

Family

ID=70285725

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020213746A Abandoned AU2020213746A1 (en) 2019-01-30 2020-01-30 A dosage regime and method for treating pulmonary arterial hypertension with rodatristat ethyl

Country Status (9)

Country Link
US (2) US11607413B2 (https=)
EP (1) EP3917531A1 (https=)
JP (1) JP2022518944A (https=)
KR (1) KR20210133953A (https=)
CN (1) CN113557022A (https=)
AU (1) AU2020213746A1 (https=)
CA (1) CA3128327A1 (https=)
MX (1) MX2021009055A (https=)
WO (1) WO2020157577A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210102887A (ko) * 2018-11-14 2021-08-20 알타반트 사이언시스 게엠베하 말초 세로토닌과 관련된 질병 또는 장애를 치료하기 위한 트립토판 하이드록실라제 1 (tph1)의 결정질 스피로사이클릭 화합물 억제제
JP2022507533A (ja) * 2018-11-16 2022-01-18 アルタバント・サイエンシズ・ゲーエムベーハー 肺動脈性高血圧症および他疾患に関連する肺動脈性肺高血圧症の治療法
US20200188399A1 (en) * 2018-12-17 2020-06-18 Altavant Sciences Gmbh Method for treating interstitial lung disease
US11607413B2 (en) 2019-01-30 2023-03-21 Altavant Sciences Gmbh Dosage regime and method for treating pulmonary arterial hypertension
US11576915B2 (en) 2019-03-15 2023-02-14 Altavant Sciences Gmbh Method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension and daily dosing
WO2023062595A1 (en) 2021-10-14 2023-04-20 Altavant Sciences Gmbh Treatment of subjects having pulmonary arterial hypertension with rodatristat ethyl

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101815534A (zh) 2007-07-11 2010-08-25 莱西肯医药有限公司 用于治疗肺动脉高压以及相关疾病和病症的方法和组合物
UA119247C2 (uk) 2013-09-06 2019-05-27 РОЙВЕНТ САЙЕНСИЗ ҐмбГ Спіроциклічні сполуки як інгібітори триптофангідроксилази
KR20210102887A (ko) 2018-11-14 2021-08-20 알타반트 사이언시스 게엠베하 말초 세로토닌과 관련된 질병 또는 장애를 치료하기 위한 트립토판 하이드록실라제 1 (tph1)의 결정질 스피로사이클릭 화합물 억제제
JP2022507533A (ja) 2018-11-16 2022-01-18 アルタバント・サイエンシズ・ゲーエムベーハー 肺動脈性高血圧症および他疾患に関連する肺動脈性肺高血圧症の治療法
US20200188399A1 (en) 2018-12-17 2020-06-18 Altavant Sciences Gmbh Method for treating interstitial lung disease
WO2020128608A1 (en) 2018-12-17 2020-06-25 Altavant Sciences Gmbh Compound for use in a method for treating sarcoidosis-associated pulmonary hypertension
US11607413B2 (en) 2019-01-30 2023-03-21 Altavant Sciences Gmbh Dosage regime and method for treating pulmonary arterial hypertension
US11576915B2 (en) * 2019-03-15 2023-02-14 Altavant Sciences Gmbh Method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension and daily dosing

Also Published As

Publication number Publication date
US11607413B2 (en) 2023-03-21
JP2022518944A (ja) 2022-03-17
CN113557022A (zh) 2021-10-26
CA3128327A1 (en) 2020-08-06
US20200237759A1 (en) 2020-07-30
WO2020157577A8 (en) 2020-10-15
MX2021009055A (es) 2021-10-22
WO2020157577A1 (en) 2020-08-06
EP3917531A1 (en) 2021-12-08
US20240041877A1 (en) 2024-02-08
KR20210133953A (ko) 2021-11-08

Similar Documents

Publication Publication Date Title
US20240041877A1 (en) Dosage regime and method for treating pulmonary arterial hypertension
US12329757B2 (en) Methods for increasing sepiapterin plasma exposure
KR101996245B1 (ko) 선택적 s1p1 수용체 아고니스트를 포함하는 약학 조합물
US20240058353A1 (en) Methods for treating gi tract disorders
US20250195529A1 (en) Compositions and methods for increasing tetrahydrobiopterin plasma exposure
US11911382B2 (en) Method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension
US20240024316A1 (en) Method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension and daily dosing
US20240197756A1 (en) Methods of treatment with neuroactive steroids
HK40062167A (en) A dosage regime and method for treating pulmonary arterial hypertension with rodatristat ethyl
HK40119071A (en) Methods for increasing sepiapterin plasma exposure
EP4642454A1 (en) Pharmaceutical combinations and compositions, and methods of use thereof
HK40051961A (en) Administration of sepiapterin without food for use in a method for increasing sepiapterin plasma exposure
HK40051961B (en) Administration of sepiapterin without food for use in a method for increasing sepiapterin plasma exposure

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application